iShares Industrial Bond ETF ENGN 深 滬
已收盤 10-03 16:00:00 美东时间
7.75
-0.390
-4.79%
華盛通- 最 高8.28
- 今 開8.28
- 成交量 8.05万股
- 最 低 7.5102
- 昨 收 8.14
- 總市值 3.96亿
- 52周最高 11.00
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 2.65
- 委 比 -56.80%
- 總股本 5110.52万
- 歷史最高 43.00
- 量 比 0.59
- 振 幅 9.46%
- 歷史最低 2.65
- 每 手 1
- 風險率 1.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多enGene Holdings Amends CEO Severance Package
An announcement from enGene Holdings ( ($ENGN) ) is now available. On October 2...
10-03 04:51
enGene Holdings Grants Inducement Equity Awards to New Hires
The latest announcement is out from enGene Holdings ( ($ENGN) ). enGene Holding...
10-02 04:39
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
enGene Holdings GAAP EPS of -$0.57
enGene Holdings press release (NASDAQ:ENGN): Q3 GAAP EPS of -$0.57. More on enGene Holdings EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript e...
09-13 01:46
Morgan Stanley Maintains Overweight on enGene Holdings, Lowers Price Target to $18
Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and lowers the price target from $19 to $18.
09-12 23:52
enGene Holdings Q3 EPS $(0.57) Misses $(0.51) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.51) by 12.87 percent. This is a 78.12 percent decrease over losses of $(0.32) per share from
09-12 04:04
enGene Holdings Reaches Target Enrollment Of 100 Patients For Pivotal Cohort Of Its Ongoing, Open-Label, Multi-Cohort Phase 2 LEGEND Trial Of Detalimogene Voraplasmid In Patients With High-Risk, NMIBC
Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achievedenGene plans to provide an update from LEGEND's pivotal cohort in 4Q 2025Biologic License Application (BLA) submission planned for
09-03 19:35
enGene Holdings Announces The U.S. FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Detalimogene Voraplasmid For Expedited Review In High-Risk, Non-Muscle Invasive Bladder Cancer
Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development toolsDesignation recognizes the potential of detalimogene to address significant unmet needenGene Holdings Inc.
06-25 20:12
enGene Holdings Reports Q2 2025 Financial Results
Engene Holdings Inc. ( ($ENGN) ) has released its Q2 earnings. Here is a breakd...
06-13 11:53
enGene Holdings Q2 EPS $(0.51) Misses $(0.49) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. This is a 34.21 percent decrease over losses of $(0.38) per share from
06-12 20:13
